Assertio Therapeutics (ASRT) Tops Q2 EPS by 20c

Assertio Therapeutics (NASDAQ: ASRT) reported Q2 EPS of $0.28, $0.20 better than the analyst estimate of $0.08. Revenue for the quarter came in at $35.4 million versus the consensus estimate of $31.63 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• St. James's Place plc (STJ:LN) (STJPF) PT Raised to GBP20.50 at Deutsche Bank
• BofA lists top 5 themes driving next $1tn in incremental semi sales